Food and Chemical Toxicology, Journal Year: 2021, Volume and Issue: 159, P. 112722 - 112722
Published: Dec. 3, 2021
Language: Английский
International Journal of Molecular Sciences, Journal Year: 2021, Volume and Issue: 22(17), P. 9472 - 9472
Published: Aug. 31, 2021
The Endocannabinoid System (ECS) is primarily responsible for maintaining homeostasis, a balance in internal environment (temperature, mood, and immune system) energy input output living, biological systems. In addition to regulating physiological processes, the ECS directly influences anxiety, feeding behaviour/appetite, emotional behaviour, depression, nervous functions, neurogenesis, neuroprotection, reward, cognition, learning, memory, pain sensation, fertility, pregnancy, pre-and post-natal development. also involved several pathophysiological diseases such as cancer, cardiovascular diseases, neurodegenerative diseases. recent years, genetic pharmacological manipulation of has gained significant interest medicine, research, drug discovery distribution components system throughout body, physiological/pathophysiological role ECS-signalling pathways many all offer promising opportunities development novel cannabinergic, cannabimimetic, cannabinoid-based therapeutic drugs that genetically or pharmacologically modulate via inhibition metabolic and/or agonism antagonism receptors ECS. This modulation results differential expression/activity may be beneficial treatment number manuscript in-depth review will investigate potential various put forth suggestion these secondary metabolites
Language: Английский
Citations
204
Journal of Clinical Medicine Research, Journal Year: 2020, Volume and Issue: 12(3), P. 129 - 141
Published: Jan. 1, 2020
Considering data from in vitro and vivo studies, cannabidiol (CBD) seems to be a promising candidate for the treatment of both somatic psychiatric disorders. The aim this review was collect dose(s), dosage schemes, efficacy safety reports CBD use adults clinical studies. A systematic search performed PubMed, Embase Cochrane library articles published English between January 1, 2000 October 25, 2019. terms used were related cannabis adults. We identified 25 studies (927 patients; 538 men 389 women), which 22 controlled trials (833 patients) three observational designs (94 five countries. Formulations, dose schemes varied significantly Varying effects randomized (RCTs), more apparent non-RCTs minor issues general. From trials, we anxiolytic with acute administration, therapeutic social anxiety disorder, psychotic disorder substance In general, heterogeneous showed substantial risks bias. Although results have been identified, considerable variation route administration employed across There evidence support single positive effect on short medium-term symptomatic improvement schizophrenia lack cognitive functioning Overall, well tolerated mild side effects. J Clin Med Res. 2020;12(3):129-141 doi: https://doi.org/10.14740/jocmr4090
Language: Английский
Citations
150
International Journal of Drug Policy, Journal Year: 2021, Volume and Issue: 99, P. 103381 - 103381
Published: Aug. 28, 2021
Cannabis use is common, especially among young people, and associated with risks for various health harms. Some jurisdictions have recently moved to legalization/regulation pursuing public goals. Evidence-based 'Lower Risk Use Guidelines' (LRCUG) recommendations were previously developed reduce modifiable risk factors of cannabis-related adverse outcomes; related evidence has evolved substantially since. We aimed review new scientific develop comprehensively up-to-date LRCUG, including their recommendations, on this basis. Targeted searches literature (since 2016) main outcomes by the user-individual conducted. Topical areas informed previous LRCUG content expanded upon current evidence. Searches preferentially focused systematic reviews, supplemented key individual studies. The results evidence-graded, topically organized narratively summarized; through an iterative expert consensus development process. A substantial body cannabis use-related harms identified varying quality. Twelve substantive recommendation clusters three precautionary statements developed. In general, suggests that individuals can if they delay onset until after adolescence, avoid high-potency (THC) products high-frequency/-intensity use, refrain from smoking-routes administration. While people are particularly vulnerable harms, other sub-groups (e.g., pregnant women, drivers, older adults, those co-morbidities) advised exercise particular caution risks. Legal/regulated should be used where possible. result in outcomes, mostly higher-risk use. Reducing help offer one targeted intervention component within a comprehensive approach They require effective audience-tailoring dissemination, regular updating as become available, evaluated impact.
Language: Английский
Citations
136
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(8), P. 4204 - 4204
Published: April 10, 2024
Phytocannabinoids, a diverse group of naturally occurring compounds extracted from the Cannabis plant, have attracted interest due to their potential pharmacological effects and medicinal uses. This comprehensive review presents intricate profiles phytocannabinoids while exploring impacts these substances on biological systems. From more than one hundred cannabinoids which were identified in plant so far, cannabidiol (CBD) tetrahydrocannabinol (THC) are two most extensively studied phytocannabinoids. CBD is non-psychoactive compound, exhibits anti-inflammatory, neuroprotective, anxiolytic properties, making it promising candidate for wide array medical conditions. THC, known its psychoactive effects, possesses analgesic antiemetic contributing therapeutic potential. In addition THC CBD, range additional shown intriguing including cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN). The endocannabinoid system, made up enzymes involved production breakdown endocannabinoids, cannabinoid receptors (CB1 CB2), endogenous ligands (endocannabinoids), essential preserving homeostasis several physiological processes. Beyond ability modify ion channels, neurotransmitter receptors, anti-oxidative pathways. complex interaction between systems offers hope novel treatment approaches lays groundwork further developments field cannabinoid-based medicine. summarizes state field, points out information gaps, emphasizes need studies fully realize
Language: Английский
Citations
17
Addiction, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 13, 2025
Abstract Background and Aims Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as potential therapeutic target due its pharmacological properties mode action in the endocannabinoid system. Recent systematic reviews (SR) on CBD SUDs have shown inconsistent results. The objective this umbrella review was determine whether alone or combination with Δ‐9‐tetrahydrocannabinol (THC) effective for managing treating SUDs. Methods Following registered protocol, we searched PubMed, Web Science Epistemonikos databases SRs, without meta‐analysis, randomized controlled trials focusing interventions dispensing CBD, THC, treat SUDs, published from 1 January 2000 15 October 2024. Screening, data extraction quality assessment AMSTAR 2 tool were performed by two researchers parallel duplicated. Results 22 SRs included, 5 which meta‐analysis. We found mixed evidence regarding efficacy manage Findings interpreted light SRs. Nabiximols, contains demonstrated positive effects cannabis withdrawal craving symptoms. Evidence supporting limited inconclusive abstinence, reduction cessation cannabis, tobacco, alcohol, opiates other psychoactive substances. Conclusion monotherapy does not appear be efficacious substance disorders. primarily exhibits when combined (THC). Existing regard outcomes related
Language: Английский
Citations
2
Behavioural Neurology, Journal Year: 2023, Volume and Issue: 2023, P. 1 - 17
Published: Oct. 12, 2023
Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the increasing significance of CBD in treating neurological conditions including epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's which present major healthcare concerns on a worldwide scale. Despite lack available therapies, been shown to possess variety pharmacological effects preclinical clinical studies, making it an intriguing competitor. review brings together most recent findings endocannabinoid neurotransmitter systems, as well anti-inflammatory pathways, that underlie CBD's modes action. Synthesized efficacy safety assessments range illnesses are included, covering human trials, vitro animal models. The investigation includes how could protect neurons, control neuroinflammation, fend off oxidative stress, manage neuronal excitability. study emphasizes existing studies future possibilities research, addressing research issues such regulatory complications contradicting results, advocates further ideal dose methodologies. By emphasizing improve patient well-being, this presents revised viewpoint suitability intervention illnesses.
Language: Английский
Citations
23
Brain Sciences, Journal Year: 2020, Volume and Issue: 10(2), P. 97 - 97
Published: Feb. 12, 2020
Increasing evidence indicates a relationship between cannabis use and psychosis risk. Specific factors, such as determinants of or the genetic profile users, appear to moderate this association. The present systematic review presents detailed up-to-date literature overview on factors that influence A search was performed according PRISMA guidelines in MEDLINE Embase, 56 studies were included. results show that, particular, frequent use, especially daily consumption high-potency are associated with higher risk developing psychosis. Moreover, several genotypes impact risk, particularly those involved dopamine function, AKT1. Finally, is an earlier onset increased transition individuals at clinical high These findings indicate changing behavior could be harm reduction strategy employed lower Future research should aim further develop specific biomarkers profiles for psychosis, thereby contributing identification highest psychotic disorder.
Language: Английский
Citations
63
Expert Opinion on Drug Metabolism & Toxicology, Journal Year: 2020, Volume and Issue: 16(6), P. 517 - 526
Published: April 9, 2020
Recent trials using cannabidiol (CBD) have shown that most acute and prolonged adverse effects of CBD are mild to moderate, with rare serious (SAEs). This review focused on analyzing SAEs their possible relation drug-drug interactions.We systematically analyzed the reported in randomized controlled (RCTs) involving administration oral for at least 1 week both healthy volunteers clinical samples.SAEs related RCT include mainly elevated transaminases, convulsion, sedation, lethargy, upper respiratory tract infections. Elevated transaminases concomitant valproate use, while infections clobazam use. Epileptic patients should be monitored when concomitantly these other antiepileptic drugs interactions.
Language: Английский
Citations
59
Neurological Sciences, Journal Year: 2020, Volume and Issue: 41(11), P. 3085 - 3098
Published: June 16, 2020
Language: Английский
Citations
58
Biochemical Pharmacology, Journal Year: 2020, Volume and Issue: 177, P. 114004 - 114004
Published: April 29, 2020
Language: Английский
Citations
54